Evaluating antimalarial efficacy in single-armed and comparative drug trials using competing risk survival analysis: a simulation study

BACKGROUND: Antimalarial efficacy studies in patients with uncomplicated Plasmodium falciparum are confounded by a new infection (a competing risk event) since this event can potentially preclude a recrudescent event (primary endpoint of interest). The current WHO guidelines recommend censoring comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Dahal, Prabin, Guerin, Philippe J., Price, Ric N., Simpson, Julie A., Stepniewska, Kasia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525412/
https://www.ncbi.nlm.nih.gov/pubmed/31101088
http://dx.doi.org/10.1186/s12874-019-0748-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525412/
https://www.ncbi.nlm.nih.gov/pubmed/31101088
http://dx.doi.org/10.1186/s12874-019-0748-2

Ejemplares similares